Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140218 · ClinicalTrials.gov registry record · Phase 1
R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by Bennett, James P., Jr., M.D., Ph.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00140218 is a Phase 1 study that has completed, run by Bennett, James P., Jr., M.D., Ph.D.. The registered enrollment target is 30 participants.
The verdict
NCT00140218, a Phase 1 study, has completed, sponsored by Bennett, James P., Jr., M.D., Ph.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.
Interventions
- DRUG R(+) pramipexole dihydrochloride monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140218
The ClinicalTrials.gov registry entry for NCT00140218 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bennett, James P., Jr., M.D., Ph.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which R(+) pramipexole dihydrochloride monohydrate is the first listed.
NCT00140218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140218 about?
NCT00140218 is a clinical study titled "R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis". The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 mont...
What is the current status of trial NCT00140218?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2005-08. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00140218?
The interventions under investigation include: R(+) pramipexole dihydrochloride monohydrate (DRUG).
Who is sponsoring clinical trial NCT00140218?
This trial is sponsored by Bennett, James P., Jr., M.D., Ph.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.